The immunological characteristics of an important group of animal-derived allergens, lipocalins, are poorly known. To explore the immunology of the lipocalin allergen Bos d 2, several mouse strains with different H-2 haplotypes were immunized with the allergen.
Introduction
Several important animal-derived aeroallergens belong to the group of proteins called lipocalins (http://www.expasy.ch/cgibin/nicesite.pl?PS00213, 1 September 2001). These allergens include the major urinary proteins of mouse and rat, Mus m 1 (1,2) and Rat n 1 (2, 3) , the dog allergens Can f 1 and Can f 2 (4), the horse allergens Equ c 1 and Equ c 2 (5, 6) , the cockroach allergen Bla g 4 (7), the major Triatoma protracta allergen (8) , and the bovine Bos d 2 (9) , which is an occupational allergen causing asthma and other work-related allergic disorders among dairy farmers. We have recently shown that the human immune response against Bos d 2 is dichotomous in that cow-asthmatic patients have high levels of Bos d 2-speci®c IgE in their sera, in contrast to the predominantly very weak cellular responses against the allergen (10) . The relationship between these two immunoparameters may in fact be a trait related to the allergenicity of lipocalins (11) . However, apart from the fact that they induce IgE production, the immunologic characteristics of lipocalin allergens are poorly known (12) . To explore the immunology of Bos d 2, murine immune responses against Bos d 2 were characterized in detail, and compared with those induced by hen egg lysozyme (HEL) and tetanus toxoid (TT) control antigens. It turned out that Bos d 2 is a very weak immunogen by all the methods used and that it exhibited a tendency to deviate the immune response towards T h 2 dominance. These features may be related to the allergenicity of lipocalin allergens. respectively), and the fusion part glutathione S-transferase (GST) (9, 14) , Pichia pastoris-produced (pp) rBos d 2 (15, 16) , HEL (Sigma, St Louis, MO; L-6876) and TT (National Public Health Institute, Helsinki, Finland). In vitro tests employed the same Bos d 2 preparation as was used for immunization. For the mapping of the epitopes of Bos d 2, 16mer peptides overlapping by 14 residues were prepared and veri®ed as reported previously (10) . Thirteen of the 71 synthesized peptides could not be tested because they proved to be insoluble in PBS. Therefore, in two cases the overlap was 8 amino acids, in two other cases 10 amino acids and in three cases 12 amino acids (10) . For additional experiments, the peptide 64 (ELEKYQQLNSERGVPN) containing the immunodominant epitope of Bos d 2 was synthesized using PerSeptive 9050 Plus automated peptide synthesizer (Millipore, Bedford, MA) with Fmoc strategy. The peptides were puri®ed by HPLC (Shimadzu, Tokyo, Japan) with a C 18 reverse phase column and acetonitrile as eluent (0.1%TFA in H 2 O/0±60% acetonitrile gradient for 60 min) and veri®ed with a MALDI-TOF mass spectrometer (Bruker, Bremen, Germany). All protein concentrations were determined by the method of Bradford (17) using the commercial BioRad (Hercules, CA) protein assay. Sterile-®ltered or g-irradiated preparations were stored either at 4°C or frozen at ±70°C. ) and CBA/s (H-2 k ) mouse strains (6±8 weeks old) were obtained from the National Laboratory Animal Center (Kuopio, Finland). Mice were maintained under pathogen-free conditions throughout the study. They were injected i.p. or s.c. at the base of the tail at 2-week intervals 1±4 times, depending on the experiment, with the antigen in alum [5 mg, prepared as described elsewhere (18) 
Immunization of mice

Measurement of antibody responses
Speci®c murine antibody responses were measured by indirect ELISA as described previously (13) , with modi®ca-tions. For measuring speci®c IgG levels of different inbred mouse strains, ELISA plates (Nunc, Roskilde, Denmark) were coated with nBos d 2 at a concentration of 1 mg/ml at 4°C overnight in the coating buffer. After the plates were blocked with diluent [0.1% (v/v) casein in PBS], they were stored frozen. Serum samples were added in duplicate (1:250, 1 h, room temperature). Bound IgG was detected by goat antimouse IgG (BioMakor, Israel; 1:1000, 0.5 h, room temperature). Next, biotinylated rabbit anti-goat IgG (Cappel, Turnhout, Belgium; 1:2000, 0.5 h, room temperature) was added. The color reaction was developed using a Vectastain ABC Elite kit (Vector, Burlingame, CA) as described previously (13) . The results were expressed as optical density (OD) values.
The levels of IgG subclasses were examined as described above with modi®cations. ELISA plates were coated with Bos d 2, HEL or TT at a concentration of 1 mg/ml (IgG1) or 50 mg/ml (IgG2a). Duplicate serum samples were incubated at 37°C for 1 h at 10-fold dilutions [1:100±1:1,000,000 (IgG1) and 1:10± 1:100,000 (IgG2a)]. Bound antibodies were detected by biotinylated anti-IgG1 (1:1000) or anti-IgG2a (1:100) antibodies (Caltag, Burlingame, CA) respectively, incubating at 37°C for 1 h. After measuring the color reaction (see above), the results were expressed as OD values at an appropriate serum dilution.
Proliferation assays
After spleens or inguinal lymph nodes were removed from the mice, single-cell suspensions were prepared and the cells of each group of mice (3±4 mice) were combined. Red blood cells were removed from spleen cell suspensions by lysing with 0.017 M Tris±0.75% NH 4 Cl (5 ml/spleen). Alternatively, the spleen cells were isolated by Lympholyte M (Cedarlane, Hornby, Ontario, Canada) density gradient centrifugation according to the protocol of the manufacturer. Finally, the cells were washed twice with the culture medium [DMEM with glutamax (Gibco, Grand Island, NY) supplemented with 20 mM 2-mercaptoethanol, 100 IU/ml penicillin, 100 mg/ml streptomycin and 10% inactivated FCS (Biological Industries, Beit Haemek, Israel)].
Spleen or lymph node cells were stimulated in triplicate at a density of 2 Q 10 5 or 10 5 cells/well respectively in the wells (0.2 ml) of round-bottomed 96-well microtiter plates (Corning, Acton, MA). In each stimulation, the concentrations of antigens (Bos d 2, HEL and TT) ranged from 12.5 to 100 mg/ml and those of the peptide containing the immunodominant T cell epitope from 0.3 to 30 mg/ml. The positive control was concanavalin A (Con A; Pharmacia Biotech, Uppsala, Sweden) at 5 mg/ml and wells without a stimulant served as the negative control. For the mapping of epitopes in Bos d 2, the spleen cells were stimulated with each of the 16mer peptides of Bos d 2 at an optimal concentration of 10 mg/ml in 12 wells. The concentrations of E. coli-produced rBos d 2, its N-and C-terminal fragments (amino acids 1±115 and 65±156 respectively), and GST were 50 mg/ml.
After addition of the stimulants, the cells were incubated for 3 days in a humidi®ed 5% CO 2 incubator at 37°C and then pulsed for 16 h with 0.5 mCi/well 
Induction and measurement of cytokine production
Spleen or lymph node cells were stimulated with Bos d 2, HEL or TT at a predetermined concentration of 100 mg/ml at an optimal density of 3 Q 10 6 cells/ml in 4-ml test tubes in a volume of 1.5 ml for 48 h (IL-2 and IFN-g) or 96 h (IL-4 and IL-5) in a humidi®ed 5% CO 2 incubator at 37°C. Positive (Con A at 5 mg/ml) and negative controls (cells with culture medium only) were included. Stimulation of the spleen or lymph node cells from mice immunized with the peptide were performed at two peptide concentrations, 3 and 30 mg/ml. An irrelevant peptide served as an additional control. After stimulation, test tubes were centrifuged, and the culture supernatants were collected, aliquoted and stored at ±70°C until examined. The levels of IL-4, IL-5 and IFN-g in the supernatants were measured by ELISA in duplicate using commercial reagents (all reagents from PharMingen, San Diego, CA) according to the manufacturer's instructions. Color reactions were developed as described for antibody measurements. Results were calculated from the standard curve using Deltasoft 3 software with a four-parameter ®t (BioMetallics, Princeton, NJ). The limits of detection were 5 pg/ml for IL-4, 30 pg/ml for IL-5 and 100 pg/ml for IFN-g. For measuring IL-2, CTLL-2 cell line was used as previously described (10) with the exception that mAb against murine IL-4 (R & D Systems, Abingdon, UK; MAB404) at a neutralizing concentration (1 mg/ml) was included in the assay. A semiquantitative estimate of IL-2 production was determined from a standard curve of rIL-2 (Strathmann Biotech, Hamburg, Germany). The limit of detection for IL-2 was 0.05 U/ml.
Statistical analysis
Statistical differences between groups were determined by the Kruskal±Wallis test and post hoc comparisons with the Mann±Whitney U-test. Values of P < 0.05 were considered signi®cant. at a concentration of 50 mg/ml) turned out to be very low (SI < 1.7, the medium background range 600±2900 c.p.m.). An increase of the immunizing allergen (50 mg/mouse of pprBos d 2), the use of different adjuvants (IFA or CFA) and an increase in the allergen concentration upon stimulation in vitro (up to 100 mg/ml of pprBos d 2) did not enhance the proliferative responses of spleen cells of BALB/c, CBA/s or B57BL/6 mice (data not shown).
Results
Mouse strains' immune responses to
IgG subclass responses to Bos d 2, HEL and TT
To further characterize the immune responses of BALB/c mice to Bos d 2, groups of mice were immunized repeatedly at 2-week intervals with 50 mg/mouse of nBos d 2, HEL or TT in alum. Figure 2(A and B) show that the speci®c IgG1 response to nBos d 2 and HEL respectively started slowly, being clearly higher than in the PBS control mice after two immunizations on day 24 (P < 0.05), whereas the antibody level against TT was already elevated after the ®rst immunization ( Fig. 2C ; P < 0.05). Immunization with nBos d 2 did not induce Bos d 2-speci®c IgG2a antibodies detectable at any serum dilution ( Fig. 2A) , whereas a response against HEL was apparent after the second immunization ( Fig. 2B ; P < 0.05) and against TT after the ®rst immunization ( Fig. 2C ; P < 0.05). The experiment was repeated twice by immunizing twice at a 2-week interval. The results were similar in all three experiments with HEL and TT, and in the ®rst two experiments with nBos d 2. In the third experiment, when pprBos d 2 was used instead of the natural preparation, low IgG2a production was observed after the second immunization when tested at a lower serum dilution of 1:10 [mean OD 0.17 T 0.04 (SEM), P = 0.02]. When mice were immunized with a higher dose of pprBos d 2 (500 mg/mouse), the anti-pprBos d 2 IgG2a level further increased slightly [mean OD 0.28 T 0.05 (SEM), P = 0.02]. However, the difference of the IgG2a levels between the groups immunized with high (500 mg/mouse) or low (50 mg/mouse) doses of pprBos d 2 was not statistically signi®cant (P > 0.05). This was also the case with IgG1 antibodies (P > 0.05), even though there was a tendency that the high dose of pprBos d 2 was more effective in inducing IgG1 synthesis than the low dose (data not shown). Figure 3 shows the IgG1/IgG2a ratios after immunization with a low or high pprBos d 2 dose, and with HEL and TT. The differences between groups immunized at 50 mg/ mouse were signi®cant (P < 0.05).
Cellular responses to Bos d 2, HEL and TT
As summarized in Fig. 4 , the mice immunized i.p. with pprBos d 2 exhibited the weakest proliferative spleen cell responses in vitro in comparison to those immunized i.p. with HEL or TT. The second immunization increased the responses, but the effect was negligible with pprBos d 2. An experiment of four immunizations with nBos d 2 at 2-week intervals gave identical results with no enhancement of spleen cell proliferation in vitro after repeated immunizations (data not shown). The differences (Fig. 4 ) between groups were statistically signi®cant (P < 0.05) except after the ®rst immunization when tested in vitro at a concentration of 12.5 mg/ml. When mice were immunized with a higher dose of pprBos d 2 (500 mg/mouse) the proliferative responses were not enhanced (SI 1.2 after the ®rst and 1.8 after the second immunization). The cytokine production of spleen cells in vitro from mice immunized i.p. with pprBos d 2, HEL or TT once or twice at a 2-week interval is summarized in Table 1 . Bos d 2 was observed to induce only a low-level production of IL-4, the differences between groups being signi®cantly different after the second immunization (P < 0.05). TT was a stronger inducer of IL-4 than HEL (P < 0.05). The IL-5 production was not statistically different between the groups (P > 0.05). HEL and TT were stronger inducers of IL-2 production than Bos d 2 (P < 0.05), and HEL and TT did not differ in this respect (P > 0.05). IFN-g production upon stimulation with the antigens was not detected. Con A stimulation induced an abundant production of the four cytokines measured in all groups (data not shown).
To verify whether the protocol of immunization in¯uenced the outcome, the immune responses were examined by immunizing the BALB/c mice s.c. with pprBos d 2 or HEL (50 mg/mouse) in CFA. While the proliferative responses of lymph node cells against both antigens were observed to be stronger than those of spleen cells in previous experiments, Bos d 2 tended to provoke weaker responses [SI 3.5 T 0.7 (SEM)] than HEL [4.2 T 1.4 (SEM)] at 100 mg/ml (three independent experiments, P > 0.05). Interestingly, Bos d 2 induced the production of IL-4 (Table 2) which was not seen with HEL (P < 0.05). The production of IL-5 and IFN-g did not differ between the immunization groups (P > 0.05).
T cell epitopes in Bos d 2
The mapping of T cell epitopes with peptides spanning the sequence of Bos d 2 revealed that the T cells of BALB/c mice recognized in Bos d 2 one immunodominant epitope (Fig. 5) . It was localized in the C-terminal end of the molecule, almost identically to the epitope G recognized by human T cells (10) . The core sequence, de®ned as those amino acids within the region shared by the three overlapping peptides (peptides 63±65) capable of inducing the strongest stimulation of spleen 
Spleen and lymph node cell responses to the immunodominant epitope of Bos d 2
To verify the immunogenicity of the immunodominant epitope of Bos d 2 and to delineate its role in determining the quality of immune response against Bos d 2, BALB/c mice were immunized i.p. with 100 mg/mouse of the peptide 64 (ELEKYQQLNSERGVPN) in alum, IFA or CFA. IFA and CFA tended to induce the stronger proliferative responses of spleen cells (Fig. 6 ), but the differences between the groups were not statistically signi®cant (P > 0.05). The immunodominant peptide induced the production of IL-5 from spleen cells (Table 3 ) in a similar manner as the complete pprBos d 2 (Table 1) . IL-2 production was also elevated. IL-4 production was low and IFN-g could not be detected. Con A stimulation induced an abundant production of the four cytokines measured in all groups (data not shown). The differences in the cytokine levels between groups immunized with different adjuvants (Table 3) were not statistically signi®cant (P > 0.05).
When BALB/c mice were immunized s.c. with the immunodominant peptide in CFA the proliferative responses of lymph node cells upon stimulation with the peptide (Table 4) appeared to be stronger than in previous experiments when the spleen cell responses of mice immunized i.p. were studied (Fig. 6, CFA) even though the optimal immunization dose was lower (10 mg/mouse s.c. or 100 mg/mouse i.p.). Interestingly, the s.c. route of immunization resulted in the strong production of IFN-g (Table 4 ), which was not the case when mice were immunized i.p. (Table 3 ). Pointing to the T h 1 dominance of the response (Table 4) , no production of IL-4 was observed while IL-5 production was lower than in previous experiments (Table  3) .
Discussion
We have shown previously that cow-dander-allergic asthmatics who show high IgE reactivity against the major allergen of cow, Bos d 2, have weak proliferative responses of peripheral blood mononuclear cells against the allergen (10) . We have lately hypothesized that the seemingly paradoxical situation with high IgE and weak cellular responses against Bos d 2 may be associated with the allergenicity of the protein (11, 12) . The situation is very interesting because it has turned out that almost all important animal-derived aeroallergens belong to the protein family of lipocalins (http://www.expasy.ch/cgi-bin/ nicesite.pl?PS00213, 1 September 2001). To circumvent the limitations associated with human studies, we conducted experiments in mice to delineate the immunologic properties of Bos d 2. It was observed that the murine immune response against Bos d 2 closely resembles that observed in humans. a Mice were immunized s.c. at the base of a tail once with the antigens (50 mg/mouse) in CFA. Ten days after the immunization, inguinal lymph node cell responses were examined as described in Methods. The results are represented as mean concentrations T SEM of three independent experiments. Medium background values were below the detection limit (see Methods). <, below the detection limit.
b P < 0.05. Table 3 . Cytokine production by spleen cells of peptideimmunized BALB/c mice a
Adjuvant IL-4 (pg/ml) IL-5 (pg/ml) IL-2 (U/ml) IFN-g (pg/ml)
a Groups of mice were immunized i.p. with 100 mg/mouse of the peptide 64 containing the immunodominant T cell epitope in alum, IFA or CFA. Ten days after immunization, spleen cell responses were examined as described in Methods. The results are represented as mean concentrations T SEM of three independent experiments upon stimulation with 30 mg/ml of the peptide. Medium is the combined medium background of all immunization groups. <, below the detection limit (see Methods). (19), it is justi®ed to say that Bos d 2 is a poor immunogen in several mouse strains.
For the assessment of the immunogenicity of a protein, the selection of proteins for comparison is important. HEL is being widely used in diverse immunological studies. In the immunization experiments of several syngenic mouse strains with different MHC haplotypes, HEL induced the lowest responses in the BALB/c mouse (19) . In contrast, TT is known to be very immunogenic (10) . Accordingly, TT induced strong IgG responses in all mouse strains used in this study (data not shown). Taking into account these considerations, our results show that Bos d 2 is a poor immunogen by several parameters, even in the responder strain BALB/c. The Bos d 2-speci®c IgG1 response started slowly and was lower than the antigen-speci®c responses of HEL-or TT-immunized mice on day 24. Although the difference in IgG2a responses was not signi®cant (P = 0.06, Kruskal±Wallis test) it was clear that Bos d 2 also induced antibodies of this subclass very poorly. Moreover, both the proliferative responses and the capacity to induce cytokine production by spleen cells after i.p. immunizations indicated that Bos d 2 is a weaker immunogen than the control antigens HEL and TT.
Repeated i.p. immunizations with nBos d 2 in alum failed to induce IgG2a antibodies in contrast to HEL or TT. The ®nding suggests that the immune response against Bos d 2 was T h 2 biased because the synthesis of IgG2a is strongly dependent on IFN-g (20, 21) . Although Bos d 2-speci®c IgG2a antibodies could be detected at a serum dilution of 1:10 after immunization with pprBos d 2, even in this case the IgG1/IgG2a ratio was signi®cantly higher with pprBos d 2-immunized mice in comparison with HEL-or TT-immunized mice (immunizations at 50 mg/mouse). The analysis of the cytokine responses of spleen cells revealed that none of the antigens was able to induce IFN-g production at a detectable level. This can be attributed to the characteristics of the BALB/c mouse, which is known to be prone to T h 2-type responses (22, 23) , to alum adjuvant (24, 25) , to the immunization route used (25) and/or to the sensitivity of the cytokine assay. On the other hand, all the antigens induced the synthesis of IL-2, which suggests that a block in IL-2 production (26) (Table 1) . Similarly, IL-5 levels secreted by lymph node cells did not differ signi®cantly between pprBos d 2 and HEL after s.c. immunization in CFA, while HEL did not induce measurable levels of IL-4 (P < 0.05; Table 2 ). We have previously shown that the secretion of type 2 cytokines IL-4 and IL-5 can be dissociated. For example, a proportion of T cell clones derived from skin of atopic dermatitis patients produced IL-5 with no detectable IL-4 (27) . This was also the case with some of the Bos d 2-speci®c clones isolated from the peripheral blood of cow-dust-asthmatic patients (10). Heeger et al. have shown that the opposite situation may also be possible. When mice were immunized with an autoantigen myelin oligodendrocyte glycoprotein the numbers of IFN-g-, IL-2-and IL-4-secreting spleen cells were high, whereas the number of IL-5-secreting cells was low or none (28) . Indeed, it seems that the synthesis of IL-4 and IL-5 can be independently regulated (29, 30) .
Our results suggest that human and murine immune systems recognize the lipocalin allergen Bos d 2 in a similar way. Allergic persons' immune responses to Bos d 2 appear to be mainly humoral, cellular responses remaining very weak; the same was true with mice. There are data suggesting that certain antigens or single T cell epitopes could account for the T h 1 or T h 2 dominance of the immune response. For example, mice made tolerant to a Leishmania major-derived antigen by transgenic expression in the thymus mounted a decreased T h 2-type response and a healing phenotype upon infection with the parasite (31) . In BALB/c mice, respiratory syncytial virus-derived protein G primes for pulmonary eosinophilia when mice are challenged with the virus (32±34). Dust mite allergen Der p 1 has been reported to promote T h 2-type responses (24) . In an autoimmune model of uveoretinitis, one epitope induced a T h 1-type response, while the other induced a T h 2-type response (35) . In another study, the injection of different antigens or peptides i.p. in IFA normally induced T h 2-type responses, but the immunization with an ovalbuminderived peptide resulted in a T h 0-type response (25) .
BALB/c mice recognized one immunodominant epitope in Bos d 2, which raises the question of the role of this epitope in a Mice were immunized s.c. at the base of a tail once with 10 mg/mouse of the peptide 64 containing the immunodominant T cell epitope in CFA. Ten days after the immunization, inguinal lymph node cell responses were examined as described in Methods. The results are represented as mean SI or cytokine concentrations T SEM of three independent experiments upon stimulation with the peptide at 30 mg/ml. In proliferation tests, medium background was in all cases <400 c.p.m. In cytokine measurements, medium background values were below the detection limit (see Methods). <, below the detection limit.
determining the quality of immune response against the allergen, especially because the peptide (ELEKYQQLNSERGVPN) containing the epitope was exactly the same as that recognized by all the cow-dust-asthmatic patients (10) . As the immunology of lipocalins is poorly characterized, it is not known whether the corresponding regions in lipocalin allergens in general are important in immune responses against them. However, the studies conducted in the BALB/c mouse with b-lactoglobulin indicated that the region in b-lactoglobulin corresponding to the immunodominant epitope found in Bos d 2 contains a T cell epitope (36±38). In the same way as observed with the antigens (Tables 1 and 2 ), our results show that the quality of immune response against the peptide with the immunodominant epitope was strongly in¯uenced by the immunization route and the responding cell type in that the lymph node cell response against the peptide was T h 1-biased after s.c. immunization in CFA (Tables 3 and 4 ). This may account for the ®nding that the immunodominant peptide failed to induce IL-4 production in lymph node cells (Table 4 ). Another possibility is that other epitopes in Bos d 2 are able to modify the response as the lymph node cell response after immunization with Bos d 2 in CFA induced IL-4 production ( Table 2 ). In addition, the outcome of immune response may be regulated by a delicate balance between the priming and stimulation doses; the molar concentrations of the peptide used both in immunization and stimulation were higher than those for Bos d 2.
Indeed, a factor in¯uencing the outcome of immune response can be the dose of antigen in priming. It has been reported that the low doses of antigen favor T h 2-type responses (39, 40) . The effect may be attributed to the low ligand density on antigen-presenting cells (APC), which has been shown to favor T h 2-type responses (41±43). As another point of view, studies with altered peptide ligands (APL) suggest that signaling through TCR can be qualitatively different due to the¯exible recognition of antigen by TCR (44, 45) . Therefore, T cell repertoire and the selection of cells becoming recruited is probably critical for the outcome of the immune response. For example, when mice were ®rst primed with a superagonist APL having an I-A b -binding capacity similar to the wild-type peptide, stimulation with the wild-type peptide resulted in the production of IFN-g mRNA, not IL-4 mRNA as was the case if mice were primed with the wild-type peptide (41) . Furthermore, the ®ndings of Murray et al. suggest that if T cells capable of recognizing the ligand ef®ciently are missing, even the high densities of the ligand on APC are not able to deviate the response to T h 1 dominance (43, 46) . As to Bos d 2, the weak immunogenicity of Bos d 2 suggests that it is recognized inef®ciently, although the contribution of other mechanisms, including peripheral tolerance (47, 48) , cannot be excluded. Bos d 2 may be presented at a low density on APC and/or the T cell repertoire recognizing Bos d 2 is de®cient. Both humans and mice contain numerous endogenous lipocalins (http://www.expasy.ch/cgi-bin/nicesite.pl?PS00213, 1 September 2001) and it can be expected that this has resulted in an extensive thymic deletion of T cells capable of recognizing endogenous lipocalins. It can be hypothesized that the surviving selfspeci®c T cells, present in low numbers in the periphery, recognize self-mimicking lipocalin allergens with their lowaf®nity TCR (49) in a suboptimal way and this favors the T h 2-deviated immune response. Taken together, this study was performed as an approach to the question of allergenicity of Bos d 2, a lipocalin allergen. To address the signi®cance of immune recognition for the allergenicity of lipocalin family of proteins, further studies are required on various factors involved, including the priming and stimulation doses of the immunodominant and other epitopes in Bos d 2, as well as on immunologic properties shared between different lipocalin allergens.
